Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 X CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

被引：12

作者：

Rutella, Sergio ^{[1
]}

Church, Sarah E. ^{[2
]}

Vadakekolathu, Jayakumar ^{[1
]}

Viboch, Elena ^{[2
]}

Sullivan, Amy H. ^{[2
]}

Hood, Tressa ^{[2
]}

Warren, Sarah E. ^{[2
]}

Cesano, Alessandra ^{[2
]}

La Motte-Mohs, Ross ^{[3
]}

Muth, John ^{[3
]}

Lelievre, Helene ^{[4
]}

Lowenberg, Bob ^{[5
]}

DiPersio, John F. ^{[6
]}

Davidson-Moncada, Jan K. ^{[3
]}

机构：

[1] Nottingham Trent Univ, John van Geest Canc Res Ctr, Nottingham, England

[2] NanoString Technol Inc, Seattle, WA USA

[3] MacroGenics Inc, Rockville, MD USA

[4] Servier, Ctr Rech Cancerol Marseille, Suresnes, France

[5] Erasmus Univ, Dept Hematol, Med Ctr, Rotterdam, Netherlands

[6] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111539

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

444

引用

页数：3

共 50 条

[41] A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma
Murthy, Guru Subramanian Guru
Kearl, Tyce J.
Cui, Weiguo
Johnson, Bryon
Hoffmeister, Karin
Szabo, Aniko
Aoki, Kazuhiro
Harrington, Alexandra M.
Carlson, Karen
Michaelis, Laura C.
Runaas, Lyndsey
Abedin, Sameem
Duvall, Adam S.
Stock, Wendy
Shah, Bijal D.
Leonard, Jessica
Pratz, Keith W.
Luger, Selina M.
Badar, Talha
Baim, Arielle
Yaghoubi, Shahriar
Atallah, Ehab L.
BLOOD, 2021, 138
[42] A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Kim, Tae Min
Alonso, Arancha
Prince, Miles
Taszner, Michal
Cho, Seok-Goo
Stevens, Don A.
Poon, Michelle
Lim, Francesca
Le Gouill, Steven
Carpio, Cecilia
Keating, Mary-Margaret
Adriaens, Lieve
Ufkin, Melanie
Sabir, Ayesha
Li, Jingjin
Jankovic, Vladimir
Zhu, Min
Brouwer-Visser, Jurriaan
Leng, Siyang
Sirulnik, L. Andres
Chaudhry, Aafia
Ambati, Srikanth R.
Seog, Kim Won
BLOOD, 2020, 136
[43] First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High RiskMyelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics
Bajel, Ashish
Garciaz, Sylvain
Desai, Pinkal
Huls, Gerwin A.
Maiti, Abhishek
Jongen-Lavrencic, Mojca
Boissel, Nicolas
De Botton, Stephane
de Leeuw, David C.
Fleming, Shaun
Zwaan, C. Michel
Arellano, Martha
Avigan, David
Saultz, Jennifer N.
Mantzaris, Ioannis
Jensen, Kyle
Wagenaar, Timothy
Mi, Gu
Ziti-Ljajic, Samira
Draganov, Dobrin
Abbadessa, Giovanni
Stein, Anthony Selwyn
BLOOD, 2023, 142
[44] Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed/refractory multiple myeloma
Aronson, Elizabeth
Purcell, Kiah
Aponte, Annel
Louw, Karen
Catamero, Donna
Lamb, Angela
Kirke, Diana
Lucas, Aimee
Jagannath, Sundar
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S195 - S195
[45] AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia
Eissenberg, Linda G.
Ritchey, Julie
Rettig, Michael P.
Fox, Judith A.
Guenot, Jeanmarie
DiPersio, John F.
BLOOD, 2018, 132
[46] A phase 1, first-in-human, open label, dose escalation study of MGD007, a humanized gpA33 x CD3 DART molecule, in patients with relapsed/refractory metastatic colorectal carcinoma
Powderly, John D.
Hurwitz, Herbert
Ryan, David P.
Laheru, Daniel A.
Pandya, Naimish B.
Lohr, Joanna
Moore, Paul A.
Bonvini, Ezio
Wigginton, Jon M.
Crocenzi, Todd S.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[47] An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.
Boissel, Nicolas
de Botton, Stephane
Thomas, Xavier G.
Rao, Ercole
Bonnevaux, Helene
Rubin-Carrez, Chantal
Guerif, Stephane
Beys, Eric
Gosselin, Alice
Bauchet, Anne-Laure
Novikov, Valery
Fernandes, Elma
Wiederschain, Dmitri
Palatinsky, Emanuel A.
Hsu, Karl
Fraenkel, Paula Goodman
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[48] AMELI-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+Acute Myeloid Leukemia (AML)
Sallman, David A.
DeAngelo, Daniel J.
Pemmaraju, Naveen
Dinner, Shira
Gill, Saar
Olin, Rebecca L.
Wang, Eunice S.
Stark, Eileen
Korngold, Ana
Figliola, Carolyn
Newhall, Kathryn J.
Lee, Daniel J.
Frattini, Mark G.
Roboz, Gail J.
MOLECULAR THERAPY, 2023, 31 (04) : 51 - 51
[49] Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+Acute Myeloid Leukemia (AML)
Sallman, David A.
DeAngelo, Daniel J.
Pemmaraju, Naveen
Dinner, Shira
Gill, Saar
Olin, Rebecca L.
Wang, Eunice S.
Konopleva, Marina
Stark, Eileen
Korngold, Ana
Haider, Asifa
Backhouse, Kate
Figliola, Carolyn
Lee, Daniel J.
Frattini, Mark G.
Brownstein, Carrie
Roboz, Gail J.
BLOOD, 2022, 140 : 2371 - 2373
[50] An asymmetrical CLL1/CD3 bispecific antibody, ABL602, exhibits CLL1 binding-dependent CD3 binding/activation and antitumor activity in acute myeloid leukemia (AML) mouse model and leukemia blasts from AML patients
Lee, E.
Lim, Y.
Lee, S.
Park, S.
Park, H.
Koh, Y.
Shin, D.
Won, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S828 - S829

← 1 2 3 4 5 →